KURN.SW Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (25 Apr 2024 @ 11:31):

Stats
Today's Volume	201 240
Average Volume	223 094
Market Cap	253.89M
EPS	CHF0 ( 2024-03-13 )
Last Dividend	CHF0 ( N/A )
Next Dividend	CHF0 ( N/A )
P/E	-18.13
ATR14	CHF0.0210 (0.30%)

Volume Correlation

Long: -0.11 (neutral)

Short: 0.99 (very strong)

Signal:(38.29) Expect same movement, but be aware

Kuros Biosciences AG Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Kuros Biosciences AG Correlation - Currency/Commodity

0.34
( neutral )

0.18
( neutral )

0.00
( neutral )

0.29
( neutral )

-0.55
( weak negative )

0.13
( neutral )

Kuros Biosciences AG Financials

Annual	2023
Revenue:	CHF33.56M
Gross Profit:	CHF27.78M (82.78 %)
EPS:	CHF-0.380

Q4	2023
Revenue:	CHF20.70M
Gross Profit:	CHF17.42M (84.18 %)
EPS:	CHF-0.240

Q2	2023
Revenue:	CHF12.87M
Gross Profit:	CHF10.36M (80.52 %)
EPS:	CHF-0.140

Q1	2023
Revenue:	CHF6.43M
Gross Profit:	CHF4.22M (65.54 %)
EPS:	CHF-0.0700

Financial Reports:

No articles found.

Kuros Biosciences AG

Kuros Biosciences AG, a biopharmaceutical company, engages in the commercialization and development of biopharmaceutical products for tissue repair and bone regeneration in the United States, the European Union, and internationally. It operates through Medical Devices, Pharmaceuticals, and Legacy Portfolio. The company's orthobiologics pipeline products include MagnetOs Granules and MagnetOs Putty in EU and US for the treatment of orthopedics, spinal, and dental problems. Its fibrin/PTH orthobiologics pipeline products comprise KUR-111, which has completed Phase 2b clinical trial for the treatment of tibial plateau fractures; and KUR-113, which completed Phase 2b clinical trial for the treatment of tibial shaft fractures, as well as is in the Phase II trial for the treatment of spinal interbody fusion. The company's sealants pipeline products include Neuroseal EU and US, synthetic tissue sealant for the prevention of cerebrospinal fluid leakage following cranial or spinal surgery. It has collaboration with Checkmate Pharmaceuticals LLC for the development of CYT003 for the treatment of oncology. The company is headquartered in Schlieren, Switzerland.